Anti-α actinin antibodies as new predictors of response to treatment in autoimmune hepatitis type 1

Alimentary Pharmacology and Therapeutics

Volumn 35, Issue 1, 2012, Pages 116-125

  Zachou, K ^a   Oikonomou, K ^a   Renaudineau, Y ^b,c   Chauveau, A ^b,c   Gatselis, N ^a   Youinou, P ^b,c   Dalekos, G N ^a  

^a UNIVERSITY OF THESSALY   (Greece)

^b Universite de Brest   (France)

^c CHU MORVAN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ACTININ ANTIBODY; AUTOANTIBODY; FILAMENTOUS ACTIN ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; AUTOIMMUNE HEPATITIS; AUTOIMMUNE HEPATITIS TYPE 1; BLOOD SAMPLING; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE EXACERBATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OPTICAL DENSITY; PREDICTION; PRIORITY JOURNAL; RELAPSE; REMISSION; TREATMENT RESPONSE;

ACTININ; ACTINS; ADOLESCENT; ADULT; AGED; AUTOANTIBODIES; BIOLOGICAL MARKERS; COHORT STUDIES; DRUG MONITORING; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS, AUTOIMMUNE; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PREDICTIVE VALUE OF TESTS; YOUNG ADULT;

EID: 83555174810     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2011.04908.x     Document Type: Article

References (42)

1. Dalekos GN, Zachou K, Liaskos C, Gatselis N,. Autoantibodies and defined target autoantigens in autoimmune hepatitis: an overview. Eur J Intern Med 2002; 13: 293-303. (Pubitemid 34812340)
2. Yeoman AD, Longhi MS, Heneghan MA,. Review article: the modern management of autoimmune hepatitis. Aliment Pharmacol Ther 2010; 31: 771-87.
3. Hennes EM, Zeniya M, Czaja AJ, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008; 48: 169-76. (Pubitemid 351975541)
4. Zachou K, Gatselis N, Papadamou G, Rigopoulou EI, Dalekos GN,. Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naïve patients. J Hepatol 2011; 55: 636-46.
5. Floreani A, Niro G, Rossa Rizzotto E, et al. Type I autoimmune hepatitis: clinical course and outcome in an Italian multicentre study. Aliment Pharmacol Ther 2006; 24: 1051-7. (Pubitemid 44386530)
6. Granito A, Muratori L, Muratori P, et al. Antibodies to filamentous actin (F-actin) in type 1 autoimmune hepatitis. J Clin Pathol 2006; 59: 280-4. (Pubitemid 43344890)
7. Czaja AJ, Cassani F, Cataleta M, Valenti P, Bianchi FB,. Frequency and significance of antibodies to actin in type 1 autoimmune hepatitis. Hepatology 1996; 24: 1068-73. (Pubitemid 26365905)
8. Zachou K, Rigopoulou E, Dalekos GN,. Autoantibodies and autoantigens in autoimmune hepatitis: important tools in clinical practice and to study pathogenesis of the disease. J Autoimmune Dis 2004; 1: 2.
9. Ma Y, Okamoto M, Thomas MG, et al. Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease. Hepatology 2002; 36: 658-64. (Pubitemid 34183971)
10. Czaja AJ, Donaldson PT, Lohse AW,. Antibodies to soluble liver antigen/liver pancreas and HLA risk factors for type 1 AIH. Am J Gastroenterol 2002; 97: 413-9. (Pubitemid 34160769)
11. Manns MP,. Antibodies to soluble liver antigen: specific marker of autoimmune hepatitis. J Hepatol 2000; 33: 326-8. (Pubitemid 30485238)
12. Baeres M, Herkel J, Czaja AJ, et al. Establishment of standardised SLA/LP immunoassays: specificity for autoimmune hepatitis, worldwide occurrence, and clinical characteristics. Gut 2002; 51: 259-64. (Pubitemid 34791458)
13. Verslype C, George C, Buchel E, Nevens F, van Steenbergen W, Fevery J,. Diagnosis and treatment of autoimmune hepatitis at age 65 and older. Aliment Pharmacol Ther 2005; 21: 695-9. (Pubitemid 40468997)
14. Makaritsis KP, Gatselis NK, Ioannou M, Petinaki E, Dalekos GN,. Polyclonal hypergammaglobulinaemia and high smooth-muscle autoantibodies titers with specificity against filamentous actin: consider visceral leishmaniasis, not just autoimmune hepatitis. Int J infect Dis 2009; 13: e157-60.
15. McGough A, Way M, DeRosier D,. Determination of the alphaactinin- binding site on actin filaments by cryoelectron microscopy and image analysis. J Cell Biol 1994; 126: 433-43.
16. Jesaitis AJ, Gizachew D, Dratz EA, Siemsen DW, Stone KC, Burrit JB,. Actin surface structure revealed by antibody imprints: evaluation of phage-display analysis of anti-actin antibodies. Protein Sci 1999; 8: 760-70. (Pubitemid 29165406)
17. Zamanou A, Samiotaki M, Panayotou G, Margaritis L, Lymberi P,. Fine specificity and subclasses of IgG anti-actin autoantibodies differ in health and disease. J Autoimmun 2003; 20: 333-44. (Pubitemid 36677525)
18. Gueguen P, Dalekos GN, Nousbaum J-B, et al. Double reactivity against actin and α-actinin defines a severe form of autoimmune hepatitis type 1. J Clin Immunol 2006; 26: 495-505.
19. Renaudineau Y, Dalekos GN, Gueguen P, Zachou K, Youinou P,. Anti-α-actinin antibodies cross-react with anti-ssDNA antibodies in active autoimmune hepatitis. Clin Rev Allergy Immunol 2008; 34: 321-5.
20. Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999; 31: 929-38. (Pubitemid 29514229)
21. Johnson PJ, McFarlane IG,. Meeting report of the International Autoimmune Hepatitis Group. Hepatology 1993; 18: 998-1005.
22. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-5. (Pubitemid 12218164)
23. Georgiadou SP, Zachou K, Rigopoulou E, et al. Occult hepatitis B virus infection in Greek patients with chronic hepatitis C and in patients with diverse non-viral hepatic diseases. J Viral Hepat 2004; 11: 358-65. (Pubitemid 38961881)
24. Gatselis NK, Georgiadou SP, Koukoulis GK, et al. Clinical significance of organ and non-organ specific autoantibodies on the response to antiviral treatment of patients with chronic hepatitis C. Aliment Pharmacol Ther 2006; 24: 1563-73. (Pubitemid 44915204)
25. Georgiadou SP, Liaskos C, Zachou K, Gabeta S, Rigopoulou EI, Dalekos GN,. Occult hepatitis B virus infection in Greek patients with autoimmune liver diseases. Liver Int 2009; 29: 434-42.
26. Mason LJ, Ravirajan CT, Rahman A, Putterman C, Isenberg DA,. Is alpha-actinin a target for pathogenic anti-DNA antibodies in lupus nephritis? Arthritis Rheum 2004; 50: 866-70. (Pubitemid 38326187)
27. Croquefer S, Renaudineau Y, Jousse S, et al. The anti-alpha-actinin test completes anti-DNA determination in systemic lupus erythematosus. Ann N Y Acad Sci 2005; 1050: 170-5. (Pubitemid 41129433)
28. Leibovitch L, George J, Levi Y, Bakimer R, Shoenfeld Y,. Anti-actin antibodies in sera from patients with autoimmune liver diseases and patients with carcinomas by ELISA. Immunol Lett 1995; 48: 129-32. (Pubitemid 26011528)
29. Treichel U, McFarlane BM, Seki T, et al. Demographics of anti-asialoglycoprotein receptor autoantibodies in autoimmune hepatitis. Gastroenterology 1994; 107: 799-804. (Pubitemid 24265528)
30. Muratori L, Cataleta M, Muratori P, Lenzi M, Bianchi FB,. Liver/kidney microsomal antibody type 1 and liver cytosol antibody type 1 concentrations in type 2 autoimmune hepatitis. Gut 1998; 42: 721-6. (Pubitemid 28261064)
31. Donaldson PT, Czaja AJ,. Genetic effects on susceptibility, clinical expression, and treatment outcome of type 1 autoimmune hepatitis. Clin Liver Dis 2002; 6: 707-25.
32. Liaskos C, Bogdanos PD, Davies ET, Dalekos GN,. Diagnostic relevance of anti-filamentous actin antibodies in autoimmune hepatitis. J Clin Pathol 2007; 60: 107-8. (Pubitemid 46142685)
33. Miyake Y, Iwasaki Y, Sakaguchi K, Shiratori Y,. Clinical features of Japanese male patients with type 1 autoimmune hepatitis. Aliment Pharmacol Ther 2006; 24: 519-23. (Pubitemid 44051328)
34. Czaja AJ,. Behavior and significance of autoantibodies in type 1 autoimmune hepatitis. J Hepatol 1999; 30: 394-401. (Pubitemid 29113226)
35. Czaja AJ, Carpenter HA, Moore SB,. Clinical and HLA phenotypes of type 1 autoimmune hepatitis in North American patients outside DR3 and DR4. Liver Int 2006; 26: 552-8.
36. Renaudineau Y, Deocharan B, Jousse S, Renaudineau E, Putterman C, Youinou P,. Anti-alpha-actinin antibodies: a new marker of lupus nephritis. Autoimmunity Rev 2007; 6: 464-8. (Pubitemid 47069972)
37. Renaudineau Y, Croquefer S, Jousse S, et al. Association of actinin-binding anti-double-stranded DNA antibodies with lupus nephritis. Arthritis Rheum 2006; 54: 2523-32. (Pubitemid 44205013)
38. Oikonomou KG, Zachou K, Dalekos GN,. Alpha-actinin: a multidisciplinary protein with important role in B-cell driven autoimmunity. Autoimmun Rev 2011; 10: 389-96.
39. Deocharan B, Qing X, Lichauco J, Putterman C,. Alpha-actinin is a cross-reactive renal target for pathogenic anti-DNA antibodies. J Immunol 2002; 168: 3072-8. (Pubitemid 34211690)
40. Qing X, Zavadil J, Crosby MB, et al. Nephritogenic anti-DNA antibodies regulate gene expression in MRL/lpr mouse glomerular mesangial cells. Arthritis Rheum 2006; 54: 2198-210. (Pubitemid 44051076)
41. Mills M, Yang N, Weinberger R, et al. Differential expression of the actin-binding proteins, alpha-actinin-2 and -3, in different species: implications for the evolution of functional redundancy. Hum Mol Genet 2001; 10: 1335-46. (Pubitemid 32640662)
42. Lan S, Wang H, Jiang H, et al. Direct interaction between alpha-actinin and hepatitis C virus NS5B. FEBS Lett 2003; 554: 289-94. (Pubitemid 37412501)